The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1421
Citalopram, Escitalopram and the QT Interval
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

In 2011, the FDA asked the manufacturers of the selective serotonin reuptake inhibitor (SSRI) citalopram (Celexa, and generics) to lower the maximum daily dosage of the drug because of a dose-related increase in the QT interval.1 Since then, some of our readers have asked whether escitalopram (Lexapro, and generics), the active enantiomer of citalopram, could have the same effect.

THE QT INTERVAL — The upper limit of normal for the QT interval is about 400 milliseconds (ms) for a heart rate of 80 and 440 ms for a heart rate of 60. Prolongation of the QT interval beyond 500 ms increases the risk of torsade de pointes, a rare but potentially fatal ventricular arrhythmia. Other risk factors for torsade de pointes include hypokalemia, hypomagnesemia, bradycardia and heart failure.2

CITALOPRAM AND ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Citalopram, Escitalopram and the QT Interval
Article code: 1421b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian